Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
Net Ocaliva ® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 net sales of $18.2 million Enrollment of Phase 3 REGENERATE interim analysis cohort anticipated complet ion by mid-2017 Data expected from two Phase 2 trials for OCA in 2017 Planned initiation of Phase 2 trial of
View HTML
Toggle Summary Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
Data Support Strong Statistical Association of PBC Biochemical Endpoint with Clinical Outcomes
View HTML
Toggle Summary Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity View HTML
Toggle Summary CONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease View HTML
Toggle Summary Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014
NEW YORK, April 4, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced presentations of key data at the
View HTML
Toggle Summary European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis
NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the European Commission has
View HTML
Toggle Summary FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid) for the Treatment of PBC
PDUFA Date is May 29, 2016 Intercept to host investor conference call today at 5:30  p.m. ET NEW YORK, April 07, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics
View HTML
Toggle Summary FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
NEW YORK, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic, underserved liver diseases, today announced that the U.S.
View HTML
Toggle Summary FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with PBC
  F irst new medicine for PBC in nearly 20 years Investor conference call Tuesday, May 31 at 8:30 a.m. ET NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to
View HTML